Christian Dreger Joins PAREXEL as Senior Vice President, PAREXEL Access and PAREXEL Consulting
September 19 2016 - 9:00AM
Business Wire
PAREXEL International Corporation (NASDAQ:PRXL), a leading
global biopharmaceutical services organization, today announced the
appointment of Christian Dreger, Ph.D., as Senior Vice President,
PAREXEL Access and PAREXEL Consulting. Dr. Dreger will oversee the
strategy and operational management for both businesses. He will
also serve on PAREXEL's Business Review Committee, the Company's
senior-most leadership team, and assist in developing and
implementing PAREXEL's strategic objectives.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160919005122/en/
Christian Dreger joins PAREXEL as Senior
Vice President, PAREXEL Access and PAREXEL Consulting. (Photo:
Business Wire)
“Christian brings deep industry experience and expertise to
PAREXEL. Throughout his career, he has held global, regional, and
local positions in emerging and established markets and in various
commercial functions and cross-functional roles with great
successes,” said Josef von Rickenbach, Chairman and Chief
Executive Officer, PAREXEL. “Christian’s leadership strengthens our
ability to deliver best-in-class commercialization, market access
and consulting services, helping our clients deliver innovative
medicines and products to patients around the globe.”
Dr. Dreger joins PAREXEL from Biogen where he served as Vice
President and Head of Global Commercial Operations, Biosimilars, in
Zug, Switzerland. He has also held international commercial and
sales positions of increasing responsibility with billion-dollar
P&L and performance management responsibilities at Cubist
Pharmaceuticals, AstraZeneca, Schering-Plough, and Roche
Pharmaceuticals and Diagnostics. He started his career as a
consultant with McKinsey & Co. in Germany.
“PAREXEL is recognized for its global expertise in consulting,
regulatory outsourcing and market access services. I look forward
to helping PAREXEL achieve our growth goals and further our
mission,” said Dr. Dreger. “In particular, I am eager to work with
our clients to support their consulting needs and to help insure
that they meet their market access and reimbursement goals.”
Dr. Dreger holds an MBA and a Ph.D. from the University of
Mannheim in Germany and St. Gallen, Switzerland, and an Executive
MBA from Northwestern University's Kellogg Graduate School of
Management. He also holds an LLB from the University of Hagen in
Germany and is a certified pharmaceutical advisor and board
director from INSEAD, Fontainebleau, France.
About PAREXEL International
PAREXEL International Corporation is a leading global
biopharmaceutical services company, providing a broad range of
expertise-based clinical research, consulting, medical
communications, and technology solutions and services to the
worldwide pharmaceutical, biotechnology and medical device
industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, and
reimbursement. PAREXEL Informatics provides advanced technology
solutions, including medical imaging, to facilitate the clinical
development process. Headquartered near Boston, Massachusetts,
PAREXEL has offices in 84 locations in 51 countries around the
world, and had approximately 18,600 employees in the fourth
quarter. For more information about PAREXEL International visit
www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its
affiliates.
This release contains “forward-looking” statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the foregoing,
the words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. Such
factors and others are discussed in the section entitled “Risk
Factors” of the Company’s most recent Annual Report on Form 10-K
and subsequent quarterly reports on Form 10-Q filed with the
Securities and Exchange Commission, which “Risk Factors” discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company’s
estimates or views as of any date subsequent to the date of this
press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160919005122/en/
MediaPAREXEL International CorporationCristi Barnett, +1
781-434-4019Cristi.Barnett@PAREXEL.comorInvestorsRon
Aldridge, +1 781-434-4753Ron.Aldridge@parexel.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Apr 2024 to May 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From May 2023 to May 2024